The global lacrimal cannula market size was valued at USD 21.0 million in 2025 and is projected to grow from USD 22.4 million in 2026 to USD 36.7 million by 2033, at a CAGR of 7.3% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 34.5% in 2025. The rising burden of lacrimal drainage disorders, including nasolacrimal duct obstruction, canalicular stenosis, chronic dacryocystitis, and congenital tear duct obstruction, is driving demand for lacrimal cannulas.
These disorders can impair normal tear drainage and cause symptoms such as excessive tearing, recurrent eye infections, irritation, and inflammation. Diagnosis requires assessment of the lacrimal drainage pathway to identify the location and extent of obstruction. Lacrimal irrigation and probing are commonly used for this purpose, with cannulas enabling controlled delivery of saline or other fluids through the canalicular system. In some cases, these procedures are also performed as part of therapeutic management to restore or evaluate drainage. Ophthalmologists manage a broader range of acquired and congenital lacrimal conditions, and the need for specialized instruments for examination and treatment increases. This supports the consumption of lacrimal cannulas across hospitals and ophthalmic clinics.
For instance, data published by the American Academy of Ophthalmology in 2025 indicate that epiphora is a very common complaint and that nasolacrimal duct obstruction (NLDO) is the most common cause of persistent epiphora. The incidence of NLDO is reported as 20.24 per 100,000. In this incidence study, NDLO accounted for 31.8% of all chronic epiphora and 67.6% of all tear drainage pathway obstructions.
The expansion of specialty eye-care infrastructure is supporting the market by increasing access to hospitals, dedicated ophthalmology centers, ambulatory surgical facilities, and subspecialty services for diagnosing and treating lacrimal drainage disorders. As more healthcare facilities develop capabilities in oculoplastic and lacrimal care, the number of settings performing procedures such as lacrimal irrigation, probing, nasolacrimal duct assessment, and canalicular interventions continues to expand. Lacrimal irrigation requires specialized cannulas to deliver saline in a controlled manner through the canalicular system, making these instruments an important component of lacrimal diagnostic practice. The development of specialized eye-care infrastructure also improves access to trained ophthalmologists and dedicated surgical teams, supporting the use of precision instruments. Expansion across emerging healthcare markets creates additional opportunities for manufacturers to supply reusable and disposable cannulas in different gauges, lengths, and configurations. As specialty facilities expand their diagnostic and surgical capabilities, the addressable base of healthcare providers using lacrimal cannulas also broadens, supporting market demand.
These disorders can impair normal tear drainage and cause symptoms such as excessive tearing, recurrent eye infections, irritation, and inflammation. Diagnosis requires assessment of the lacrimal drainage pathway to identify the location and extent of obstruction. Lacrimal irrigation and probing are commonly used for this purpose, with cannulas enabling controlled delivery of saline or other fluids through the canalicular system. In some cases, these procedures are also performed as part of therapeutic management to restore or evaluate drainage. Ophthalmologists manage a broader range of acquired and congenital lacrimal conditions, and the need for specialized instruments for examination and treatment increases. This supports the consumption of lacrimal cannulas across hospitals and ophthalmic clinics.
For instance, data published by the American Academy of Ophthalmology in 2025 indicate that epiphora is a very common complaint and that nasolacrimal duct obstruction (NLDO) is the most common cause of persistent epiphora. The incidence of NLDO is reported as 20.24 per 100,000. In this incidence study, NDLO accounted for 31.8% of all chronic epiphora and 67.6% of all tear drainage pathway obstructions.
The expansion of specialty eye-care infrastructure is supporting the market by increasing access to hospitals, dedicated ophthalmology centers, ambulatory surgical facilities, and subspecialty services for diagnosing and treating lacrimal drainage disorders. As more healthcare facilities develop capabilities in oculoplastic and lacrimal care, the number of settings performing procedures such as lacrimal irrigation, probing, nasolacrimal duct assessment, and canalicular interventions continues to expand. Lacrimal irrigation requires specialized cannulas to deliver saline in a controlled manner through the canalicular system, making these instruments an important component of lacrimal diagnostic practice. The development of specialized eye-care infrastructure also improves access to trained ophthalmologists and dedicated surgical teams, supporting the use of precision instruments. Expansion across emerging healthcare markets creates additional opportunities for manufacturers to supply reusable and disposable cannulas in different gauges, lengths, and configurations. As specialty facilities expand their diagnostic and surgical capabilities, the addressable base of healthcare providers using lacrimal cannulas also broadens, supporting market demand.
Global Lacrimal Cannula Market Report Segmentation
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends across each sub-segment from 2021 to 2033. For this study, the analyst has segmented the global lacrimal cannula market report based on product, design, gauge size, application, end-use, and region:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Reusable Lacrimal Cannulas
- Disposable Lacrimal Cannulas
Design Outlook (Revenue, USD Million, 2021 - 2033)
- Straight
- Curved
Gauge Size Outlook (Revenue, USD Million, 2021 - 2033)
- 19G-21G
- 22G-24G
- 25G-27G
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Lacrimal Irrigation
- Obstruction Management
- Lacrimal Surgery & Repair
End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Ophthalmic Clinics & Eye Centers
- Ambulatory Surgical Centers
- Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Thailand
- Latin America
- Argentina
- Brazil
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Lacrimal Cannula Market Variables, Trends, & Scope
Chapter 4. Lacrimal Cannula Market: Product Estimates & Trend Analysis
Chapter 5. Lacrimal Cannula Market: Design Estimates & Trend Analysis
Chapter 6. Lacrimal Cannula Market: Gauge Size Estimates & Trend Analysis
Chapter 7. Lacrimal Cannula Market: Application Estimates & Trend Analysis
Chapter 8. Lacrimal Cannula Market: End Use Estimates & Trend Analysis
Chapter 9. Lacrimal Cannula Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- BEAVER VISITEC INTERNATIONAL (TPG Capital)
- FCI
- Surtex Instruments Limited
- Madhu Instruments Pvt. Ltd.
- Microtrack Surgicals
- Corza Ophthalmology
- RUMEX International Co.
- Geuder
- EAGLE LABS (INNOVIA MEDICAL)
- Aspen Surgical Products, Inc. (Audax Private Equity)
- Sterimedix (Synergetics USA)
- Bausch + Lomb.
- Reea carewell products
- Tecfen Medical
